関連する実験動画
Updated: Aug 10, 2026

07:25
Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
内生性ノルエピネフリンとエピネフリンが欠けているマウスのベータ-アドレナジック受容体キナーゼ-1の収縮性および減少
1Department of Medicine, University of North Carolina at Chapel Hill, 27599-7075, USA.
Circulation
|May 25, 1999
まとめ
ノルエピネフリン (NE) を生成できないマウスは,心臓の収縮性が改善されたことを示した. これは,NEがベータアドレネルゲン受容体キナーゼ1 (betaARK1) 活性を増やすことで心不全を引き起こす可能性があることを示唆しています.
科学分野:
- 心血管生理学 心血管の生理学
- 分子心臓病学 分子心臓病学
- 薬理学 薬理学とは
背景:
- 高濃度のノレピネフリン (NE) は,拡張性心筋症候群におけるベータアドレナジック受容体 (betaAR) のダウンレギュレーションに寄与する.
- このプロセスには,ベータアドレナジック受容体キナーゼ1 (βARK1) の増加が関与しています.
研究 の 目的:
- 持続的なNE刺激が心臓信号の悪化の主な原因であるかどうかを調査する.
- 障害のあるNE合成を持つマウスモデルを特徴付けるため.
主な方法:
- ドーパミンβ-ヒドロキシラーゼ (dbh-/-) が欠けている遺伝子標的マウスを作成しました.
- 左心室マイクロマノメトリーを用いた in vivo 心臓収縮率の評価.
- 孤立した成人の肌細胞の収縮性を評価した.
- 測定されたβARK1活性とタンパク質レベル.
- 定量化されたベータAR密度とGタンパク質レベル.
主要な成果:
- dbhが欠けていたマウスは,in vivoおよびin vitroで心臓の収縮性が強化されたことを示した.
- dbh-/-マウスでは,βARK1の活性とタンパク質濃度の低下が観察されました.
- ベータARに対する高親和性アゴニストの結合の増加は,受容体密度やGタンパク質レベルの変化なしに発生しました.
結論:
- NE合成が欠けているマウスは,ベータARK1.1の減少に関連した収縮性の向上を示しています.
- このdbh-/-マウスモデルは,心不全の病原性におけるNEの役割を研究するのに価値があります.
関連する概念動画
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

